Interferon therapy for renal cell carcinoma in hemodialysis patients: Report of two patients

International Journal of Urology

Volumn 7, Issue 5, 2000, Pages 189-192

  Hanazawa, Kisaburo ^a,c   Tanaka, Michio ^a   Watanabe, Ryota ^a   Fujime, Makoto ^b  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NONE   (Japan)

Author keywords

Hemodialysis; Interferon; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; BLOOD TOXICITY; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; FEVER; HEMODIALYSIS PATIENT; HUMAN; KIDNEY CARCINOMA; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 0034102896     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2000.00158.x     Document Type: Article

References (10)

1. 1 Hirsch MS, Tolkoff-Rubin NE, Kelly AP, Rubin RH. Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. J. Infect. Dis. 1983; 148: 335.
2. 2 Cheeseman SH, Rubin RH, Stewart JA et al. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. N. Engl. J. Med. 1979; 300: 1345-9.
3. 3 Kawano S, Tazaki Y, Mizoguchi H, Takahashi S, Nomura Y, Ogata J. Renal cell carcinoma of a hemodialysis patient: A case report. Nishinihon J. Urol. 1990; 52: 511-14.
4. 4 Uchihara M, Izumi N, Sakai Y et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: Increased serum levels of interferon. Nephron 1998; 80: 51-6.
5. 5 Rostaing L, Chatelut E, Payen JL et al. Pharmacokinetics of α-IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implication. J. Am. Soc. Nephrol. 1998; 9: 2344-8.
6. 6 Kimura K. A cooperative phase I-II study of HLBI in patients with malignant tumors. Jpn. J. Chemother. 1984; 11: 1324-31.
7. 7 Benci A, Caremani M, Menchetti D, Sasdelli M, Giusti PB. Low-dose leukocyte interferon-α therapy in dialysed patients with chronic hepatitis C. Curr: Med. Res. Opin. 1998; 14: 141-4.
8. 8 Bocci V, Pacini A, Muscettola M, Pessina GP, Paulesu E, Bandinelli L. The kidney is the main site of interferon catabolism. J. Interferon Res. 1982; 2: 309-14.
9. 9 Wills RJ. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet. 1990; 19: 390-9.
10. 10 Bocci V, Pacini A, Bandinelli L, Pessina GP, Muscettola M, Pauleusu L. The role of liver in the catabolism of human α-and β-interferon. J. Gen. Virol. 1982; 60: 397-400.